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Outcomes Following TEVAR for Acute and
Chronic Type B Aortic Dissection
James Sampson,MarjanMujib,Mark A. Patterson,Marc A.
Passman, Thomas C. Matthews, William D. Jordan. Uni-
versity of Alabama at Birmingham, Birmingham, AL
Objectives: To review clinical outcomes of endovascu-
lar treatment of type B aortic dissection.
Methods: All patients treated for type B aortic dissec-
tion between 2006-2011 were identified from a prospec-
tively maintained registry. Health systems charts and med-
ical correspondences were reviewed. Measured outcomes
included resolution of the indication for intervention, ad-
ditional procedures, and survival at 30 days and 1 year.
Results: 55 patients were treated with TEVAR for type
B dissection (mean age, 6114 years), 39 (71%) for acute
dissections and 16 (29%) for chronic dissections. Indica-
tions for treatment were pain (21), malperfusion (13),
aneurysm (6), uncontrolled hypertension (6), expansion
(5), and rupture (4). Success, defined by relief of indication
and freedom from death or re-intervention at 30 days, was
achieved in 87% of patients. Twenty-six additional proce-
dures were performed in 22 patients prior to, or at the time
of TEVAR. These included debranching procedures (8),
renal stenting (7), Iliac stenting (5), iliac exposure or
conduit creation (2), mesenteric stenting (2), thrombec-
tomy (1), and tube thoracostomy (1). Left subclavian ar-
tery coverage was required in 23 patients. Spinal ischemia
occurred in 4 patients, and lumbar drainage performed in 2
patients. Three patients required reintervention during the
study period. Survival was 93% at thirty-days and 78% at
one year.
Conclusions: TEVAR is effective in the treatment of
the complications of both acute and chronic type B aortic
dissection. Additional procedures are frequently necessary,
but early results indicate favorable outcomes, while re-
intervention is rare.
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Perioperative Use of Dextran Is Associated with Car-
diac Complications after Carotid Endarterectomy
Alik Farber1, Tze-Woei Tan1, Jeffrey Kalish1, Naomi M.
Hamburg1, Robert Eberhardt1, Gheorghe Doros1, Denis
V. Rybin1, Philip P. Goodney2, Jack L. Cronenwett2, for
the Vascular Study Group of New England. 1Boston Med-
ical Center/ Boston University School of Medicine and
Public Health, Boston, MA; 2Dartmouth-Hitchcock Med-
ical Center, Lebanon, NH
Objectives: Although dextran has been theorized to
diminish the risk of stroke after carotid endarterectomy-
(CEA) variation exists in its use. We evaluated outcomes of
dextran use in patients undergoing CEA to clarify its utility.
Methods: We studied all primary CEA performed by
71 surgeons within the Vascular Study Group of New
England database (2003-2010). Patients were stratified by
perioperative dextran use. Outcomes included periopera-
tive death, stroke, myocardial infarction(MI) and conges-
tive heart failure(CHF). Group and propensity score
matching were performed for risk adjusted comparisons,
and multivariable logistic regression was used to examine
associations between dextran use and outcomes.
Results: There were 6,641 CEA performed, with dex-
tran used in 334(5%) procedures. Dextran and No Dextran
patients were similar in age(70 years) and symptomatic
status(25%). Other differences between the cohorts dimin-
ished after adjustment (Table). In crude, group-matched,
and propensity matched analyses, stroke/death rate was
similar between cohorts (1.2%),while Dextran patients
were more likely to suffer perioperative MI (2.4% vs 1.0%;
Table.
EVAR OAR
Male (n1820) Female (n453) P value Male (n1436) Female (n484) P value
Age (years), median
All 74 77 .001 71 73 .001
Intact 74 76 .001 70 73 .001
Ruptured 72 78 .001 73 77 .001
AAA diameter (mm), mean
All 58.4 56.6 .004 64.7 59.7 .001
Elective 57.2 55.4 .001 60.8 57.3 .001
Symptomatic 65.4 62.5 0.39 69.3 65.4 .24
Ruptured 75.3 72.4 0.56 79.1 70.8 .004
30-day mortality (%)
All 2 2 0.46 8 9 .39
Intact 1 1 .58 2 4 .05
Ruptured 29 26 1.00 33 48 .03
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